Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vutrisiran
Pharma
Alnylam scraps Amvuttra ATTR heart disease interim analysis
After Onpattro's positive ATTR-CM readout, Alnylam feels "emboldened" and wants to have the "strongest possible datasets" for Amvuttra, an exec said.
Angus Liu
Oct 27, 2022 11:48am
Alnylam's high-stakes Onpattro heart trial posts partial win
Aug 3, 2022 10:22am
Alnylam's Onpattro follow-up med wins FDA approval
Jun 14, 2022 9:00am